CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Healthcare analytics platform H1 has acquired Ribbon, backed by a16Z and General Catalyst

From TechCrunch

By Marina Temkin

January 8, 2025

Healthcare analytics platform H1 has acquired Ribbon, backed by a16Z and General Catalyst

Healthcare analytics platform H1 has acquired Ribbon, backed by a16Z and General Catalyst

H1, a healthcare data analytics platform serving the pharmaceutical industry with data on over 10 million healthcare professionals, has acquired Ribbon, a startup that helps patients find doctors that are supported by their insurance.

Financial terms of the deal have not been disclosed. The last time that Ribbon — founded in 2016 and a Y Combinator alum — raised money was in 2021, when it closed a $43.5 millio Series B that valued it at $283.5 million, per PitchBook data.

Many startups that haven’t secured funding in over three years are increasingly facing pressure, with many becoming acquisition targets or facing imminent closure. But Arial Katz, co-founder and CEO of H1, told TechCrunch that Ribbon “was not a company that was running out of business.” H1 is paying a combination of stock and cash to acquire Ribbon, which is earning “well over tens of millions in revenue,” he added.

Ribbon had raised $55 million overall from investors that include Andreessen Horowitz, General Catalyst and Rock Health.

For its part, H1 has raised around $200 million and was last valued around $773 million in 2022. PitchBook notes it also raised an undisclosed amount in 2024.

H1 had its sights on combining with Ribbon for years, Katz told TechCrunch. The two companies collect similar information but serve different client sets, he said.

“I’ve been trying to buy Ribbon for three years,” Katz said, adding that the two companies have many synergies because they collect similar data.

Ribbon serves patients by providing details about doctors’ expertise, cost and quality. Ribbon’s data is purchased by healthcare navigation companies like Transcarent and Rightway and then is made available to patients through health insurance sites. H1 meanwhile tends to work with pharmaceutical and other companies in the healthcare business providing data and other insights to help them, for example, set up and run clinical trials.

Although Ribbon was likely not a fire sale, we expect to see many startups this year struggling to raise follow-on funding and reaching the end of their runways. They’ll become acquisition targets, if they don’t shut down altogether.

View original article on techcrunch.com

Most Recent

Disney agrees to hire the majority of Character.AI’s workforce

After chatbot startup Character.AI filed for bankruptcy earlier this week, many of its employees will have the opportunity to take jobs at Disney.

Oct 18, 2026

Elorian’s first AI model wants to reason with images, not just about them

According to Elorian's evaluations, Glimpse outperforms even GPT-6 Astra on scientific chart reasoning and short-form video captioning, with competitive results on other visual reasoning tasks.

Oct 16, 2026

Tressfecta wants to make hair braiding a less arduous task for hairstylists

Tressfecta builds products for textured hair. Its first project is a tool called Plait Pilot that helps braiders with the initial process of separating hair from packs before braiding begins.

Oct 16, 2026

Veritas expands its anti-counterfeit chip to jewelry, trophies, and fragrance bottles

Counterfeiters are getting better at replicating brands' marks and passing off dupes, known as "superfakes," as genuine items. A startup called Veritas wants to tackle the problem with its own chip that verifies goods.

Oct 16, 2026

Similar Posts

Innovaccer aims to become healthcare’s AI powerhouse with $275M Series F

When it comes to data, perhaps no sector has as much of it and in as many distinct silos as the healthcare industry. Hundreds of millions of patient records reside within various electronic health records (EHRs) maintained by vendors like Epic, Cerner and Athena. Insurance companies hold extensive data sets on coverage, reimbursement rates, and patient demographics. Pharmacies and laboratories contribute further data points on medication usage and diagnostic results. Over the last decade or so

Jan 9, 2025

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI, a startup building AI solutions that can handle non-diagnostic patient-facing tasks, secured a massive $141 million Series B at a valuation of $1.64 billion led by Kleiner Perkins, the company announced Thursday. The funding comes nine months after Hippocratic AI raised a $53 million round from General Catalyst and Andreessen Horowitz and five months after raising $17 million from Nvidia. The startup is less than two years old. While most healthcare-generative AI companies focus

Jan 9, 2025

Lotus Health nabs $35M for AI doctor that sees patients for free

This AI doctor is licensed in all 50 states, the startup says. The deal was led by CRV and Kleiner Perkins.

Feb 3, 2026

Health benefits platform Thatch reaches $1B valuation as healthcare costs surge

Thatch, a platform that lowers healthcare costs for employers while expanding plan choices for workers, has raised $108 million at a $1 billion valuation from existing investors: The General Partnership, Index Ventures, General Catalyst, and Andreessen Horowitz. The new fundraise comes 17 months aft

Sep 15, 2026